Efficacy and safety of valsartan in hypertensive Taiwanese patients: Post-marketing surveillance study

References

• Kjeldsen SE, Brunner HR, McInnes GT, Stolt P. Valsartan in the treatment of hypertension. Aging Health. 2005;1:27–36.
   Google Scholar
• Black H, Bailey J, Zappe D, Samuel R. Valsartan: More than a decade of experience. Drugs. 2009;69:2393–2414.
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Angeli F, Mazzotta G, Ambrosio G, Reboldi G. Angiotensin receptor blockers in hypertension. New insights from Japan. Hypertens Res. 2010;33:394–397.
   PubMedGoogle Scholar
• Biswas PN, Wilton LV, Shakir SW. The safety of valsartan: Results of a postmarketing surveillance study on 12881 patients in England. J Hum Hypertens. 2002;16:795–803.
   PubMed Web of Science ®Google Scholar
• McInnes GT. Clinical advantage of valsartan. Cardiology. 1999;91:14–18.
   PubMed Web of Science ®Google Scholar
• Oparil S, Dyke S, Harris F, Kief J, James D, Hester A, . The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension. Clin Ther. 1996;18:797–810.
   PubMed Web of Science ®Google Scholar
• Holwerda NJ, Fogari R, Angeli P, Porcellati C, Hereng C, Oddou-Stock P, . Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: Efficacy and safety compared with placebo and enalapril. J Hypertens. 1996;14:1147–1151.
   PubMed Web of Science ®Google Scholar
• Fogari R, Mugellini A, Zoppi A, Marasi G, Pasotti C, Poletti L, . Effects of valsartan compared with enalapril on blood pressure and cognitive function in elderly patients with essential hypertension. Eur J Clin Pharmacol. 2004;59:863–868.
   PubMed Web of Science ®Google Scholar
• Corea L, Cardoni O, Fogari R, Innocenti P, Porcellati C, Provvidenza M, . Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: A comparative study of the efficacy and safety against amlodipine. Clin Pharmacol Ther. 1996;60:341–346.
   PubMed Web of Science ®Google Scholar
• Malacco E, Varì N, Capuano V, Spagnuolo V, Borgnino C, Palatini P, . A randomized, double-blind, active-controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: The Val-Syst study. Clin Ther. 2003;25:2765–2780.
   PubMed Web of Science ®Google Scholar
• Hedner T, Oparil S, Rasmussen K, Rapelli A, Gatlin M, Kobi P, . A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension. Am J Hypertens. 1999;12:414–417.
   PubMed Web of Science ®Google Scholar
• Black HR, Graff A, Shute D, Stoltz R, Ruff D, Levine J, . Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: Efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril. J Hum Hypertens. 1997;11:483–489.
   PubMed Web of Science ®Google Scholar
• Cifkova R, Peleska J, Hradec J, Rosolová H, Pintérová E, Zeman K, . Valsartan and atenolol in patients with severe essential hypertension. J Hum Hypertens. 1998;12:563–567.
   PubMed Web of Science ®Google Scholar
• Neuhauser H, Radtke A, von Brevern M, Lezius F, Feldmann M, Lempert T. Burden of dizziness and vertigo in the community. Arch Intern Med. 2008;168:2118–2124.
   PubMed Web of Science ®Google Scholar
• Kirk JK. Angiotensin-II receptor antagonists: Their place in therapy. Am Fam Physician. 1999;59:3140–3148.
   PubMed Web of Science ®Google Scholar
• Weir MR, Ferdinand KC, Flack JM, Jamerson KA, Daley W, Zelenkofske S. A non-inferiority comparison of valsartan/hydrochlorothiazide combination versus amlodipine in black hypertensives. Hypertension. 2005;46:508–513.
   PubMed Web of Science ®Google Scholar
• Nouh MS, Halim SA. Efficacy and tolerability of valsartan in patients with mild to moderate essential hypertension. Saudi Med J. 2002;23:521–525.
   PubMedGoogle Scholar
• Weir MR. Angiotensin II receptor blockers: The importance of dose in cardiovascular and renal risk reduction. J Clin Hypertens (Greenwich). 2004;6:315–323.
   PubMedGoogle Scholar
• Weber M. Clinical safety and tolerability of losartan. Clin Ther. 1997;19:604–616.
   PubMed Web of Science ®Google Scholar
• Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667–1675.
   PubMed Web of Science ®Google Scholar
• Lacourcière Y, Poirier L, Hebert D, Assouline L, Stolt P, Rehel B, . Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: An 8-week, randomized, double-blind, parallel-group trial. Clin Ther. 2005;27:1013–1021.
   PubMed Web of Science ®Google Scholar
• Calhoun DA, Glazer RD, Pettyjohn FS, Coenen PD, Zhao Y, Grosso A. Efficacy and tolerability of combination therapy with valsartan/hydrochlorothiazide in the initial treatment of severe hypertension. Curr Med Res Opin. 2008;24:2303–2311.
   PubMed Web of Science ®Google Scholar
• Mallion JM, Carretta R, Trenkwalder P, Martinez JF, Tykarski A, Teitelbaum I, . Valsartan/hydrochlorothiazide is effective in hypertensive patients inadequately controlled by valsartan monotherapy. Blood Press Suppl. 2003;1:36–43.
   PubMedGoogle Scholar
• Neutel JM, Bedigian MP. Efficacy of valsartan in patients aged 65 years with systolic hypertension. Clin Ther. 2000;22:961–969.
   PubMed Web of Science ®Google Scholar
• Pool J, Oparil S, Hedner T, Glazer R, Oddou-Stock P, Hester A. Dose-responsive antihypertensive efficacy of valsartan, a new angiotensin II-receptor blocker. Clin Ther. 1998;20:1106–1114.
   PubMed Web of Science ®Google Scholar
• Su TC, Bai CH, Chang HY, You SL, Chien KL, Chen MF, Chen HJ, . Evidence for improved control of hypertension in Taiwan:. 1993–2002. J Hypertens. 2008;26:600–606.
   PubMed Web of Science ®Google Scholar
• Nixon RM, Müller E, Lowy A, Falvey H. Valsartan vs other angiotensin II receptor blockers in the treatment of hypertension: A meta-analytical approach. Int J Clin Pract. 2009;63:766–775.
   PubMed Web of Science ®Google Scholar
• Ruilope LM, Malacco E, Khder Y, Kandra A, Bönner G, Heintz D. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: The VAST study. Clin Ther. 2005;27:578–587.
   PubMed Web of Science ®Google Scholar
• Fogari R, Zoppi A, Carretta R, Veglio F, Salvetti A, Italian Collaborative Study Group. Effect of indomethacin on the antihypertensive efficacy of valsartan and lisinopril: A multicentre study. J Hypertens. 2002;20:1007–1014.
   PubMed Web of Science ®Google Scholar
• Lacourcière Y, Lefebvre J, Nakhle G, Faison EP, Snavely DB, Nelson EB. Association between cough and angiotensin converting enzyme inhibitors versus angiotensin II antagonists: The design of a prospective, controlled study. J Hypertens Suppl. 1994;12:S49–53.
   Google Scholar
• Pylypchuk GB. ACE inhibitor versus angiotensin II blocker-induced cough and angioedema. Ann Pharmacother. 1998;32:1060–1066.
   PubMed Web of Science ®Google Scholar
• Weir MR, Weber MA, Neutel JM, Vendetti J, Michelson EL, Wang RY. Efficacy of candesartan cilexetil as add-on therapy in hypertensive patients uncontrolled on background therapy: A clinical experience trial. Am J Hypertens. 2001;14:567–572.
   PubMed Web of Science ®Google Scholar
• Mancia G, Laurent S, Agabati-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, . Reappraisal of European guidelines on hypertension management: A European Society of Hypertension Task Force document. J Hypertens. 2009;27:2121–2158.
   PubMed Web of Science ®Google Scholar